Soluble PD‐L1 is a promising disease biomarker but does not reflect tissue expression in classic Hodgkin lymphoma

Reverse signaling via PD-L1 supports malignant cell growth and survival in classical Hodgkin lymphoma

(2019) Shahrzad Jalali et al.   Blood Cancer Journal

Expression pattern of PD-L1 and PD-L2 in classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, and gray zone lymphoma

(2018) Yosuke Tanaka et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

CD83 is a new potential biomarker and therapeutic target for Hodgkin lymphoma

(2018) Ziduo Li et al.   HAEMATOLOGICA

High Serum Level of Soluble Programmed Death Ligand 1 is Associated With a Poor Prognosis in Hodgkin Lymphoma

(2018) Xiaofang Guo et al.   Translational Oncology

CD83 is a new potential biomarker and therapeutic target for Hodgkin lymphoma

(2018) Ziduo Li et al.   HAEMATOLOGICA

Programmed cell death protein-1 (PD-1)-expression in the microenvironment of classical Hodgkin lymphoma at relapse during anti-PD-1-treatment

(2018) Stephanie Sasse et al.   HAEMATOLOGICA

Soluble PD-1 and PD-L1 as potential biomarkers for classical Hodgkin lymphoma

(2018) Priscilla Brito da Silva et al.   HEMATOLOGICAL ONCOLOGY

Expression of PD-1 and PD-L1 increase in consecutive biopsies in patients with classical Hodgkin lymphoma

(2018) Peter Hollander et al.   PLoS One

Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer

(2017) Xinxin Zhu et al.   Oncotarget

Biomarkers for evaluation of treatment response in classical Hodgkin lymphoma: comparison of sGalectin-1, sCD163 and sCD30 with TARC

(2016) Wouter J. Plattel et al.   BRITISH JOURNAL OF HAEMATOLOGY

PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome

(2016) Margaretha G.M. Roemer et al.   JOURNAL OF CLINICAL ONCOLOGY

The Analysis of CD83 Expression on Human Immune Cells Identifies a Unique CD83+-Activated T Cell Population

(2016) Xinsheng Ju et al.   JOURNAL OF IMMUNOLOGY

Programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and EBV-encoded RNA (EBER) expression in Hodgkin lymphoma

(2015) Semra Paydas et al.   ANNALS OF HEMATOLOGY

VEGF-A modulates expression of inhibitory checkpoints on CD8+T cells in tumors

(2015) Thibault Voron et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Baseline serum TARC levels predict therapy outcome in patients with Hodgkin lymphoma

(2012) Maike Sauer et al.   AMERICAN JOURNAL OF HEMATOLOGY

Serum CD163 and TARC as Disease Response Biomarkers in Classical Hodgkin Lymphoma

(2012) K. Jones et al.   CLINICAL CANCER RESEARCH

Plasma thymus and activation-regulated chemokine as an early response marker in classical Hodgkin's lymphoma

(2011) W. J. Plattel et al.   HAEMATOLOGICA

Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma

(2010) M. R. Green et al.   BLOOD

Increased programmed death-1+ tumor-infiltrating lymphocytes in classical Hodgkin lymphoma substantiate reduced overall survival

(2009) Simone Muenst et al.   HUMAN PATHOLOGY

Serum chemokine levels in Hodgkin lymphoma patients: highly increased levels of CCL17 and CCL22

(2008) Marijke Niens et al.   BRITISH JOURNAL OF HAEMATOLOGY